Stocktoria
Nautilus Biotechnology, Inc. NAUT
Nasdaq · XNAS · stock · Laboratory Analytical Instruments · website · IPO 2020-08-07
Nautilus Biotechnology, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| R&D expense | $41.1M | $50.5M | $47.3M | $37.7M | $29.4M |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$59.0M | -$70.8M | -$63.7M | -$57.9M | -$50.3M |
| EPS (diluted) | $-0.47 | $-0.56 | $-0.51 | $-0.46 | $-0.60 |
| Operating cash flow | -$50.7M | -$59.1M | -$51.7M | -$45.8M | -$39.2M |
| Free cash flow | -$52.0M | -$61.3M | -$54.2M | -$48.1M | -$41.5M |
| Cash & equivalents | $12.4M | $27.6M | $19.4M | $114.5M | $185.6M |
| Total assets | $191.1M | $242.7M | $305.6M | $350.1M | $398.4M |
| Total liabilities | $34.1M | $34.0M | $40.2M | $35.1M | $34.9M |
| Shareholders' equity | $157.0M | $208.7M | $265.4M | $314.9M | $363.6M |
Source: SEC EDGAR filings · CIK 0001808805 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.